Bone Health Management in Prostate Cancer Patients Receiving Androgen Deprivation Therapy by Dhanapal, Vishnuprabha & Reeves, David J.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2012
Bone Health Management in Prostate Cancer
Patients Receiving Androgen Deprivation Therapy
Vishnuprabha Dhanapal
David J. Reeves
Butler University, dreeves@butler.edu
Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Oncology Commons, Pharmaceutical Preparations Commons, and the Pharmacy and
Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Dhanapal, Vishnuprabha and Reeves, David J., "Bone Health Management in Prostate Cancer Patients Receiving Androgen
Deprivation Therapy" (2012). Scholarship and Professional Work – COPHS. Paper 210.
http://digitalcommons.butler.edu/cophs_papers/210
Oncology
Pharmacy
Practice
Journal of
Original Article
Bone health management in prostate
cancer patients receiving androgen
deprivation therapy
Vishnuprabha Dhanapal
Henry Ford Hospital, Detroit, MI, USA
David J Reeves
St Vincent Indianapolis Hospital and Butler University, Indianapolis, IN, USA
Abstract
Purpose: Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the
first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture
Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National
Comprehensive Cancer Network and the National Osteoporosis Foundation have developed osteoporosis guidelines.
This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health
based on national guidelines compliance.
Methods: A retrospective chart review of patients receiving a LHRH agonist at our institution was conducted. Data
collection commenced upon Institutional Review Board approval and included demographics, past medical history,
medication regimen, history of androgen deprivation therapy, bone health and its management. The ten year fracture
risk calculated with the collected information using the FRAX tool.
Results: A total of 174 subjects included with a mean age of 65.5 years, 71.8% had stage II prostate cancer, 97.7%
received the LHRH agonist leuprolide for a mean of 13.8 18.1 months. In addition to ADT, 57% of patients had 2 risk
factors for developing osteoporosis. The risk of sustaining a major facture increased from 4% to 5.6% after the initiation
of ADT (P¼<0.001). The risk for sustaining a hip fracture rose from 1.3% to 2.2% (P¼<0.001). National guideline
compliance was found to be 9%, 5% and 3% respectively for obtaining Dual Energy X-ray Absorptiometry (DEXA) scans,
calcium supplementation, and vitamin D supplementation.
Conclusion: In addition to predisposing risk factors for osteoporosis, ADT significantly increases the fracture risk in the
prostate cancer population. There is room for improvement in the management of bone health as some intervention
could have been made in over 90% of patients evaluated.
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Background
Prostate cancer is the most common malignancy in
males and the second leading cause of cancer-related
mortality.1 It is estimated that one in six men will
develop prostate cancer in their lifetime.2 However,
the relative survival rates for prostate cancer are high:
100% at 5 years, 91% at 10 years, and 76% at 15
years.2 Thus, minimizing the morbidity and mortality
associated with the management of prostate cancer is at
the forefront of caring for this population.
Management of prostate cancer is based on risk
stratiﬁcation and involves a variety of treatment strat-
egies (Table 1). The proliferation of prostate cancer
cells is dependent on the binding of dihydrotestoster-
one, a derivative of testosterone with a higher binding
aﬃnity, to the androgen receptor. Androgen-depriva-
tion therapy (ADT) (given as a depot luteinizing
hormone-releasing agonist with or without an antian-
drogen) is the recommended treatment for men with
locally advanced prostate cancer, biochemical relapse
after resection or radiation, and metastatic prostate
cancer.3 ADT can be achieved surgically via bilateral
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orchiectomy or pharmacologically (Table 2), most com-
monly utilizing luteinizing hormone-releasing hormone
(LHRH) agonists. Adverse eﬀects associated with ADT
include: hot ﬂashes, sexual dysfunction, hypogonadism,
and osteoporosis.
Patients receiving ADT undergo a rapid decline in
bone mineral density (BMD) during the ﬁrst 6 to 12
months of initiating therapy. Osteoporosis is often
under-diagnosed and under-prevented in men despite
an estimated prevalence of 2 million and another 12
million men are at risk.4,5 The major acquired causes
of osteoporosis in men include: alcoholism, hypogo-
nadism, and glucocorticoid therapy, of which the
latter two are often found concomitantly in patients
with prostate cancer. The use of ADT to manage pros-
tate cancer indirectly and directly increases the fracture
risk in this population. Indirectly, fracture risk is
increased due to decreased muscle mass and increasing
fall risk as a result of iatrogenic hypogonadism. The
mechanism by which testosterone aﬀects bone density
is not completely understood. Androgens mediate oste-
oblast proliferation and diﬀerentiation, and increase
bone matrix production and osteocalcin secretion pre-
sumably via the androgen receptor on osteoblasts.6
Thus, ADT is believed to directly increase bone turn-
over and decrease BMD. Several prospective studies
have established that BMD is signiﬁcantly decreased
in men receiving ADT in comparison to control
groups. Interestingly, BMD loss in this population
exceeded that seen in early menopause.7 Fracture
rates in men with prostate cancer who received ADT
were described as a near-doubling of spinal fracture
risk and a ﬁve-fold increase in hip fracture risk
compared to matched controls.8,9
The World Health Organization (WHO) has devel-
oped and implemented the Fracture Risk Assessment
Tool (FRAX) to predict the 10-year risk of a major
fracture (deﬁned as a fracture in the clinical spine,
shoulder, or forearm) and hip fracture.10 The FRAX
tool accounts for the patient’s age, gender, body mass
index (BMI), history of previous fracture in the patient
or their parents, smoking status, alcohol consump-
tion, and the presence of rheumatoid arthritis or
other secondary risk for osteoporosis and BMD.
Additionally, the WHO, National Osteoporosis
Foundation (NOF), and the National Comprehensive
Cancer Network (NCCN) created guidelines (Table 3)
to prevent and manage osteoporosis.5,10,11 This study
aims to characterize the fracture risk (based on the
FRAX tool) and the current management of bone
health based on compliance to national osteoporosis
guidelines.
Methods
A retrospective chart review of patients receiving a
LHRH agonist at our institution between 1 January
2007 and 1 January 2009 was identiﬁed via a pharmacy
database. Patients were included if they were between
18 and 89 years, received at least one dose of a LHRH
Table 1. Prostate cancer risk stratification
Risk Characteristicsa Treatment modalities
Low T1–T2a Active surveillance
Gleason 6 Radical prostatectom
PSA 10 ng/mL External beam radiation
Intermediate T2b–T2c ADT 4–6 months
Gleason 7
PSA 10–20 ng/mL
High T3–T4 Radical prostatectomy
Gleason 8 to 10 External beam radiation
PSA> 20 ng/mL ADT 2–3 years
Continuous ADT
aPatient only needs to meet one of the criteria listed under
‘Characteristics’ to fall into risk category.
Table 3. National guideline recommendationsa
Patient counseling
Smoking cessation
Limiting alcohol consumption
Weight-bearing exercise
BMD testing
Men 50 to 69 based on risk factors
All men 70 years old
Calcium and vitamin D supplementations
Men 50 years calcium 1200mg per day
Men 50 years vitamin D 800–1000 IU per day
Bisphosphate therapy
FRAX risk 3% for hip fracture
FRAX risk 20% for major fracture
Osteopenia/osteoporosis on BMD
aBased on guidelines created by the NOF and the NCCN.
Table 2. Pharmacologic agents utilized to achieve ADT
Non-steroidal antiandrogens
Flutamide
Bicalutamide
Nilutamide
Steroidal antiandrogens
Megestrol
LHRH agonist
Leuprolide
Goserelin
Triptorelin
LHRH antagonist
Degarelix
Other
Ketoconazole
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agonist between the above-mentioned dates, and had a
diagnosis of prostate cancer. Patients with metastatic
bone lesions or incomplete records were excluded.
Electronic medical and paper records for these patients
were reviewed retrospectively from the time care was
initiated until either metastatic lesions were identiﬁed
in the bones or 1 August 2009 (whichever occurred
ﬁrst). Data collection commenced upon Institutional
Review Board approval and included demographics,
past medical history, medication regimen, history of
ADT, and bone health and its management. Collected
information on bone health included: fracture history,
BMD screening data, assessment of secondary risk fac-
tors for osteoporosis, and bone health management.
The 10-year fracture risk was calculated with the col-
lected information using the FRAX tool. Study end-
points included characterizing the fracture risk in the
prostate cancer population receiving ADT utilizing the
FRAX tool and characterizing the current management
of bone health based on osteoporosis guideline compli-
ance. Duration of ADT was calculated based on the
total exposure for patients receiving continuous hor-
mone therapy and duration of the most recent cycle
of ADT in patients being treated intermittently.
Descriptive statistics were used for demographic data
analysis and to characterize the current management of
bone health. Paired t-test was used to compare 10-year
fracture pre- and post-ADT (where p< 0.05 identiﬁes a
signiﬁcant value).
Results
A total of 462 charts were reviewed, of which 174 sub-
jects were included in the study with a mean age of 65.5
years. The remaining patients were excluded for the
following reasons: presence of bone metastasis
(n¼ 213), age >89 (n¼ 43), and incomplete records
(n¼ 32). The majority (71.8%) of patients had stage
II prostate cancer at the time of initial diagnosis and
received a LHRH agonist for a mean of 13.8 18.1
months. The group with stage II disease at diagnosis
comprised patients receiving ADT intermittently for
biochemical relapse (57.9%), neoadjuvantly to radia-
tion or surgery (33.4%), and continuously for cancer
progression (8.7%). Demographic data are summarized
in Table 4. Fifty-four percent of patients received ADT
for less than 6 months, while 20% and 26% of the
patients received 7 to 12 months and >12 months of
ADT, respectively.
In addition to ADT, 57% of the patients had 2
additional risk factors for developing osteoporosis
(Figure 1). The risks factors assessed were age over
70, Caucasian ancestry, BMI <25, smoking/alcohol
intake, steroid exposure, and secondary risk factors
for osteoporosis development (excluding ADT).
Utilizing the FRAX tool, the 10-year estimated fracture
risk was calculated. The risk for developing a major
facture, deﬁned as fracture of the clinical spine,
shoulder, or forearm, increased from 4% prior to
ADT to 5.6% after the initiation of ADT (p 0.001).
Similarly, the risk for sustaining a hip fracture rose
from 1.3% to 2.2% (p 0.001).
General counseling regarding adverse eﬀects associ-
ated with ADT was documented in 15% and another
16% received speciﬁc counseling regarding the eﬀects of
ADT on bones. Bone health assessment was not docu-
mented in 69% of patients. Compliance to national
osteoporosis guideline recommendations was found to
be 9%, 5%, and 3% for obtaining dual energy X-ray
absorptiometry (DEXA) scans, calcium supplementa-
tion, and vitamin D supplementation (Figure 2).
Bisphosphonate therapy was indicated in 10% of the
patients, of which 40% received one. Overall compli-
ance (deﬁned as obtaining a DEXA scan,
Table 4. Demographics
Average SD Range
Age (years) 65.5 9.7 47–88
N %
Race African American 105 60.3
Caucasian 67 38.5
Hispanic 2 1.1
Smoking Current 39 22.4
Former 50 28.7
Alcohol 3 drinks/day 6 3.4
<3 drinks/day 168 96.6
Stage Stage II 125 71.8
Stage III 29 16.7
Stage IV 20 11.5
Agent Leuprolide 170 97.7
Triptorelin 4 2.3
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Figure 1. Risk factors for osteoporosis.
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supplementing calcium, vitamin D, and administration
of a bisphosphonate if indicated) was 3.9%.
Nine percent of patients (n¼ 15) were documented
to have undergone a DEXA scan and results were avail-
able for nine patients. The average age of patients was
77.2 4.6 years, 50% were Caucasian, and the average
BMI was 27.2. Patients receiving a DEXA scan were on
ADT for an average of 31.5 months. The FRAX score
in this population accounting for ADT for sustaining a
major fracture was 6.1% and 2.7% for hip fracture
(Figure 3). Sixty-six percent of patients had a BMD
in the osteopenic or osteoporotic range. Calcium and
vitamin D supplementations were indicated in all these
patients and supplemented in 22% of them.
Bisphosphate therapy was indicated in six patients
and initiated in 3.
Discussion
Fractures lead to back pain, decreased functional capac-
ity, increased risk of future fractures, higher health care
costs, and increased incidence of institutionalization and
hospitalizations.12,13 Additionally, fractures in men are
associated with a decreased quality of life and increased
mortality.14 The overall healthcare costs associated with
osteoporosis has been estimated to approach $17 billion
annually.13
Metastatic prostate cancer bone lesions lead to bone
disruption and pathological fractures, which are an
important cause of morbidity. Initiation of adjunctive
bisphosphonate in this subpopulation is a standard of
care to prevent skeletal-related events.15 Our study
focused on osteoporotic risk rather than on pathologi-
cal fractures as a consequence of the treatment of pros-
tate cancer. In an eﬀort to decrease confounders,
patients with metastatic bone lesions were excluded.
The demographics of the population evaluated in this
study is similar to those of other studies evaluating
osteoporosis in men receiving ADT.16–19
Many patients presenting with prostate cancer have
pre-existing risk factors for sustaining a fracture prior
to the initiation of ADT. In fact, over 70% of all pros-
tate cancer cases occur in men >65 years of age with
a median age of 68 years.20 Pre-existing osteopenia/
osteoporosis, subclinical vitamin D deﬁciency, and a
plethora of comorbidities are also found in this popu-
lation.21 Unmodiﬁable risk factors identiﬁed in this
study population included median age and Caucasian
ancestry. Other identiﬁed risk factors include previous
or current smoking status, BMI< 25 kg/m2, and sec-
ondary risk factors (i.e., osteogenesis imperfecta, diabe-
tes mellitus type 1, drugs (excluding ADT)). Fifty-seven
percent of patients had 2 assessable risk factors.
However, the true number of risk factors is most
likely higher, given the retrospective nature of this
study and the lack of documentation regarding second-
ary risk factors.
BMD is considered the gold standard for diagnosing
and assessing management of osteoporosis.22 The dura-
tion of ADT directly correlates to the magnitude of
decrease in BMD and subsequently to increased frac-
ture risk. An analysis of over 50,000 men from the
Surveillance, Epidemiology and End Results (SEER)
program and medicare databases compared the risk
of fracture in men with a diagnosis of prostate cancer
who were treated with ADT versus those not receiving
ADT.23 No diﬀerences between study arms were
detected in the year prior to ADT initiation.
However, the proportion of patients with osteoporosis
(6.92% vs. 3.69%, p< 0.001), fracture (19.37 vs. 12.63,
p< 0.001), and fracture resulting in hospitalization
(5.19% vs. 2.37%, p< 0.001) was higher in the ADT
arm 1–5 years after treatment compared to patients
who did not receive ADT. The risk of fracture was
also found to directly correlate with the number of
doses of LHRH agonist received. Due to the retrospec-
tive nature of our study, only a snapshot of androgen
exposure was assessed. At ﬁrst glance, over half the
patients received ADT for 6 months. However, over
50% of the population was receiving intermittent
hormone therapy (IHT) and only the last cycle (deﬁned
as therapy resuming after a break of greater 3 months)
1.3
4
5.6
2.2
0
1
2
3
4
5
6
7
Major fracture Hip fracture
% Unmodified
Modified
p< 0.001 
p< 0.001 
Figure 3. FRAX 10-year estimated fracture risk.
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Figure 2. Compliance to national guideline measures.
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was used to calculate duration. Therefore, the total
exposure to ADT is likely to be greater than the calcu-
lated value. This method of calculating duration was
selected as many patients were on IHT for numerous
years and previously managed at other facilities; hence
records were not available. Although increased dura-
tion of ADT directly correlates to increasing risk, stud-
ies also indicate that the greatest rate in decline in
BMD is actually within the ﬁrst 6–12 months of
ADT.24 Additionally, recent studies support extended
duration of ADT and the direct correlation between
duration and signiﬁcance of adverse eﬀects is well doc-
umented.25–27 Thus, the overwhelming majority of
patients with prostate cancer are at risk for bone-
related complications upon the initiation of ADT.
Calcium and vitamin D supplementations are known
to improve BMD and ultimately decrease fracture inci-
dence.28,29 Supplementations of both calcium and vita-
min D are recommended for the majority of patients
receiving ADT. Caution is needed when supplementing
calcium in patients with metastatic bone lesions, as
these patients are at risk for developing hypercalcemia.
Bisphosphate therapy is recommended in prostate
cancer patients receiving ADT with a 20% risk of a
major fracture or 3% risk of hip fracture based on
FRAX score.5,10,11 Although long-term data on the
incidence of fracture in men with prostate cancer treated
with bisphosphonate therapy are unavailable, short-
term results support its use.30 Our study indicates that
calcium and vitamin D supplementations were indicated
in the overwhelming majority of patients; however,
they were rarely provided. Similarly, out study shows
that there is room for improvement in bisphosphate
supplementation.
A retrospective study conducted by Tanvetyanon
evaluated 184 patients receiving ADT for 1 year to
identify independent predictors of receiving at least one
physician initiated intervention to prevent or treat oste-
oporosis.21 Interventions evaluated included: BMD
evaluation via DEXA scan, initiation of bisphospho-
nates, calcium, vitamin D, calcitonin, or estrogen.
Similar to the results of our study, most patients had
multiple risk factors for osteoporosis and the majority
of patients did not receive any intervention. Thirty-
three physicians made 58 interventions in 27 patients.
Overall, 14.7% of patients (95% CI, 9.5 20.0%)
received at least one intervention. In our study,
12.6% of the patients received at least one intervention.
Of the six patients that received a DEXA scan in the
above study, ﬁve had osteoporosis and one had osteo-
penia. The only predictor of receiving a intervention
was the presence of bone metastasis. Fifty-one percent
of interventions were made by primary care physicians,
27.3% by non-oncology related specialists, and 21.2%
by oncologists. Inability to assess primary care
interventions is a limitation to our study as it was con-
ducted at a independent cancer center without complete
access to records of non-oncology related physicians.
Thus, interventions made outside our institution may
not have been documented.
The FRAX tool, validated assessment software cre-
ated by the WHO, predicts the 10-year estimated frac-
ture risk based on known clinical risk factors with or
without BMD test results.31 To the investigators’
knowledge, our study is the ﬁrst study characterizing
the fracture risk in the prostate cancer population uti-
lizing the FRAX tool. As hypothesized, including ADT
as a secondary risk factor signiﬁcantly increased the 10-
year risk of both a major fracture and a hip fracture.
Even with the addition of ADT to the risk calculation,
the average 10-year risk of sustaining a major fracture
was well below the 20% threshold necessitating bispho-
sphonate supplementation per guidelines. However, the
median 10-year risk for sustaining a hip fracture with
the addition of ADT was 2.7%, trending toward the
3% risk necessitating bisphosphonate therapy. One of
the major limitations of the FRAX tool is the need to
primarily input dichotomous data. The tool is unable to
account for extent of exposure to glucocorticoid, alco-
hol, smoking, or ADT. Additionally, minimal informa-
tion regarding family history of fractures was identiﬁed
in the medical records; thus, the tool assumed that this
risk was not present. Therefore, the estimated 10-year
fracture risk maybe underestimated in our population.
Compliance to national guidelines was assessed in
ﬁve areas: obtaining a DEXA scan, supplementation
of calcium, supplementation of vitamin D, bisphospho-
nate therapy, and overall compliance (deﬁned as meet-
ing all four previously mentioned interventions in
indicated patients). Baseline assessment by clinicians
was identiﬁed as either general (mention of discussion
of adverse eﬀects (ADRs) associated with ADT) or
speciﬁc (documentation of discussion of speciﬁcally
bone-related risks, documentation of calcium/vitamin
D addition, bisphosphonate therapy, or obtaining
DEXA scan). Low compliance to guideline measures
may be subsequent to the lack of risk perception.
Osteoporosis is frequently considered a disease of
small-framed Caucasian or Asian elderly women.
Sixty-nine percent of patients had no documentation
of discussion of adverse eﬀects associated with ADT.
Additionally, due to the primary concern of preventing
further spread of malignancy, the management of
ADRs, speciﬁcally bone-health complications which
remain silent until fracture incidence, may not be at
the forefront of priorities. The management of prostate
cancer is truly multidisciplinary as patients are seen by
one of or a combination of medical oncology, radiation
oncology, and surgical oncology services, increasing the
diﬃculty of managing complications. Due to the
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retrospective nature of this study, the low compliance
rates may also be due to a lack of documentation. One
method to improve compliance is educating the clini-
cians about the fracture risk in this population and
available preventative measures.
Similar to our study, Wilcox et al.32 conducted a ret-
rospective analysis of veterans with prostate cancer
receiving ADT to characterize risk factors and manage-
ment of bone health in this population. A total of 174
patients were included with a mean age of 76, and the
mean duration of ADT was 21 months. Thirteen per-
cent of men underwent a DEXA scan, 19% received
calcium and vitamin D supplementations, and 11%
of the patients received bisphosphonate therapy.
Investigators concluded this population has pre-existing
risk factors for osteoporosis and received inadequate
evaluation and treatment for osteoporosis.
Of the patients receiving a DEXA scan within our
institution, 2/3 had osteopenia or osteoporosis. When
reviewing the characteristics of these patients, it was
easily noted these patients were at high risk based on
age and BMI alone. However, DEXA scans were not
ordered at baseline but, rather, only after patients
received ADT for a prolonged period of time. DEXA
scans were ordered for conﬁrmation of clinical assess-
ment rather then for prevention or treatment. No sub-
sequent follow-up scans were conducted to evaluate
management strategies.
Conclusion
Traditionally considered a comorbidity in the elderly
female population, this study has characterized the sub-
stantial bone-health related complications in the pros-
tate cancer population receiving ADT. However, the
true risk is likely much greater as discussed above.
There is great room for improvement in compliance
to national guidelines as some intervention could have
been made in over 90% of patients evaluated.
Educating the multidisciplinary teams caring for pros-
tate cancer patients regarding the risk of bone-related
complications is one modality of optimizing care. As
pharmacist-driven initiatives, collaborative practice
agreement, and medication therapy management
become routine responsibilities of the profession, opti-
mization of the prevention and management of osteo-
porosis in prostate cancer patients receiving ADT can
and should be actively incorporated in to daily practice.
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